vs

Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Astera Labs, Inc. is the larger business by last-quarter revenue ($308.4M vs $37.2M, roughly 8.3× Organogenesis Holdings Inc.). On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (93.4% vs -57.1%). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (100.3% CAGR vs -46.5%).

Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

ALAB vs ORGO — Head-to-Head

Bigger by revenue
ALAB
ALAB
8.3× larger
ALAB
$308.4M
$37.2M
ORGO
Growing faster (revenue YoY)
ALAB
ALAB
+150.5% gap
ALAB
93.4%
-57.1%
ORGO
Faster 2-yr revenue CAGR
ALAB
ALAB
Annualised
ALAB
100.3%
-46.5%
ORGO

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
ALAB
ALAB
ORGO
ORGO
Revenue
$308.4M
$37.2M
Net Profit
$80.3M
Gross Margin
76.3%
30.8%
Operating Margin
20.1%
-185.1%
Net Margin
26.0%
Revenue YoY
93.4%
-57.1%
Net Profit YoY
152.4%
EPS (diluted)
$0.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALAB
ALAB
ORGO
ORGO
Q1 26
$308.4M
$37.2M
Q4 25
$270.6M
$225.6M
Q3 25
$230.6M
$150.9M
Q2 25
$191.9M
$101.0M
Q1 25
$159.4M
$86.7M
Q4 24
$141.1M
$126.7M
Q3 24
$113.1M
$115.2M
Q2 24
$76.8M
$130.2M
Net Profit
ALAB
ALAB
ORGO
ORGO
Q1 26
$80.3M
Q4 25
$45.0M
$43.7M
Q3 25
$91.1M
$21.6M
Q2 25
$51.2M
$-9.4M
Q1 25
$31.8M
$-18.8M
Q4 24
$24.7M
$7.7M
Q3 24
$-7.6M
$12.3M
Q2 24
$-7.5M
$-17.0M
Gross Margin
ALAB
ALAB
ORGO
ORGO
Q1 26
76.3%
30.8%
Q4 25
75.6%
Q3 25
76.2%
Q2 25
75.8%
Q1 25
74.9%
72.6%
Q4 24
74.0%
75.5%
Q3 24
77.7%
76.7%
Q2 24
77.9%
77.6%
Operating Margin
ALAB
ALAB
ORGO
ORGO
Q1 26
20.1%
-185.1%
Q4 25
24.7%
28.1%
Q3 25
24.0%
13.7%
Q2 25
20.7%
-12.5%
Q1 25
7.1%
-30.9%
Q4 24
0.1%
8.1%
Q3 24
-7.9%
5.4%
Q2 24
-31.7%
-10.7%
Net Margin
ALAB
ALAB
ORGO
ORGO
Q1 26
26.0%
Q4 25
16.6%
19.4%
Q3 25
39.5%
14.3%
Q2 25
26.7%
-9.3%
Q1 25
20.0%
-21.7%
Q4 24
17.5%
6.1%
Q3 24
-6.7%
10.7%
Q2 24
-9.8%
-13.1%
EPS (diluted)
ALAB
ALAB
ORGO
ORGO
Q1 26
$0.44
Q4 25
$0.25
$0.31
Q3 25
$0.50
$0.11
Q2 25
$0.29
$-0.10
Q1 25
$0.18
$-0.17
Q4 24
$1.23
$0.05
Q3 24
$-0.05
$0.09
Q2 24
$-0.05
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALAB
ALAB
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$148.3M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.5B
Total Assets
$1.7B
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALAB
ALAB
ORGO
ORGO
Q1 26
$148.3M
$91.4M
Q4 25
$167.6M
$93.7M
Q3 25
$140.4M
$63.7M
Q2 25
$162.3M
$73.1M
Q1 25
$86.4M
$110.0M
Q4 24
$79.6M
$135.6M
Q3 24
$126.1M
$94.3M
Q2 24
$421.1M
$89.9M
Total Debt
ALAB
ALAB
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
ALAB
ALAB
ORGO
ORGO
Q1 26
$1.5B
Q4 25
$1.4B
$300.1M
Q3 25
$1.3B
$255.1M
Q2 25
$1.1B
$233.2M
Q1 25
$1.0B
$242.9M
Q4 24
$964.8M
$262.9M
Q3 24
$889.6M
$278.5M
Q2 24
$845.3M
$263.5M
Total Assets
ALAB
ALAB
ORGO
ORGO
Q1 26
$1.7B
$520.0M
Q4 25
$1.5B
$598.7M
Q3 25
$1.4B
$509.8M
Q2 25
$1.3B
$461.1M
Q1 25
$1.1B
$467.4M
Q4 24
$1.1B
$497.9M
Q3 24
$983.1M
$446.3M
Q2 24
$915.5M
$443.2M
Debt / Equity
ALAB
ALAB
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALAB
ALAB
ORGO
ORGO
Operating Cash FlowLast quarter
$74.6M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.93×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALAB
ALAB
ORGO
ORGO
Q1 26
$74.6M
Q4 25
$95.3M
$39.4M
Q3 25
$78.2M
$3.1M
Q2 25
$135.4M
$-32.9M
Q1 25
$10.5M
$-19.9M
Q4 24
$39.7M
$10.9M
Q3 24
$63.5M
$8.7M
Q2 24
$29.8M
$4.7M
Free Cash Flow
ALAB
ALAB
ORGO
ORGO
Q1 26
Q4 25
$76.6M
$34.8M
Q3 25
$65.9M
$844.0K
Q2 25
$133.3M
$-36.5M
Q1 25
$6.0M
$-23.6M
Q4 24
$24.3M
$7.6M
Q3 24
$46.8M
$6.1M
Q2 24
$28.5M
$2.9M
FCF Margin
ALAB
ALAB
ORGO
ORGO
Q1 26
Q4 25
28.3%
15.4%
Q3 25
28.6%
0.6%
Q2 25
69.5%
-36.1%
Q1 25
3.7%
-27.2%
Q4 24
17.2%
6.0%
Q3 24
41.4%
5.3%
Q2 24
37.1%
2.2%
Capex Intensity
ALAB
ALAB
ORGO
ORGO
Q1 26
Q4 25
6.9%
2.1%
Q3 25
5.3%
1.5%
Q2 25
1.1%
3.6%
Q1 25
2.8%
4.2%
Q4 24
10.9%
2.7%
Q3 24
14.8%
2.2%
Q2 24
1.7%
1.4%
Cash Conversion
ALAB
ALAB
ORGO
ORGO
Q1 26
0.93×
Q4 25
2.12×
0.90×
Q3 25
0.86×
0.14×
Q2 25
2.64×
Q1 25
0.33×
Q4 24
1.61×
1.43×
Q3 24
0.71×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons